Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, "Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkin's Lymphoma of any of the Phase 3 Non-Hodgkin's Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007."

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkin's Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patient's own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:7/30/2014)... July 30, 2014 PuraMed BioScience ® ... of over-the-counter (OTC) medicinal and healthcare products, announced ... M name along with the name,s red and ... the trademarked name MigraPure ®  going forward. ... PuraMed,s homeopathic, natural migraine pain reliever will be ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... 2011 Reportlinker.com announces that a new market research ... Epidemiology: Lupus http://www.reportlinker.com/p0484924/Epidemiology-Lupus.html ... 404,300 prevalent cases of systemic lupus erythematosus (SLE) in ... cases in women between 45 and 64 years of ...
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... manufacturing, and marketing of branded generic and proprietary pharmaceuticals ... unaudited financial results for the first quarter ended March ... market opens in the United States. Simcere,s management will ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Lupus 2Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011 2
(Date:7/30/2014)... LTC Consumer, an independent, free online service to help ... Instant Quote tool on its website, LTCconsumer.com , announced ... are free and unlimited. , The Instant Quote tool ... including age, gender, and state of residence – and delivers ... to enter any contact information to get started). There is ...
(Date:7/30/2014)... Washington, DC (PRWEB) July 30, 2014 ... its appreciation to U.S. Sens. Thad Cochran (R-MS) ... push for improvements in telemedicine coverage under Medicare, ... Cochran and Wicker, both Mississippi Republicans, introduced the ... bill to a House version, H.R. 3306, introduced ...
(Date:7/30/2014)... 2014 Hospitals continually face the ... care that their practitioners provide. During a recent ... discussed the importance of establishing effective peer review ... and quality of care. , With regard ... Rowe elaborated on setting performance expectations, conducting regular ...
(Date:7/30/2014)... Bay Aquarium Research Institute (MBARI) have observed a deep-sea ... yearslonger than any other known animal. Throughout this time, ... from predators. This amazing feat represents an evolutionary balancing ... having plenty of time to develop within their eggs, ... little or no food. , Every few months for ...
(Date:7/30/2014)... 30, 2014 Frozen shoulder (Adhesive capsulitis) affects ... to develop this nasty condition which occurs most frequently in ... last up to two and half years if not treated. ... and with good reason: it can render your shoulder so ... is, if you aren't in too much pain to get ...
Breaking Medicine News(10 mins):Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... ANGELES, Oct. 16 D.I.S.C. (Diagnostic and,Interventional Spinal and ... "Official Medical Center" of the N.H.L.,s Los,Angeles Kings hockey ... into the sports marketing arena in a very significant,way. ... natural fit for us and we,are thrilled to be ...
... Surgical,Company (Nasdaq: STAA ) today announced that ... ended September 29, 2007 on Tuesday, October,30, 2007 ... a conference call,and webcast on Tuesday, October 30, ... Company,s third quarter and current corporate developments. The,dial-in ...
... American,Cancer Society (ACS) inaugurated the National Breast Cancer ... Mammography Day. The NBCAM,was conceived and funded by ... petrochemicals, and its U.S. subsidiary,Zeneca Pharmaceuticals. Zeneca is ... of breast cancer, even though it is toxic ...
... While it is commonly thought that men with low ... or sexual deviance, new research has found the men ... sex education previously taken. , A team of ... and without an intellectual disability and a history of ...
... Oct. 16 Expected to be,her family,s Halloween treat, ... 1 pound, 10 ounces. Today, the five-year-old of,Allentown, Pennsylvania ... Catharine, who was born 16 weeks early, measuring only ... than half a million,babies born preterm each year in ...
... More Than,100,000 Kids, WASHINGTON, Oct. 16 As ... that would increase the,state cigarette tax to fund children,s ... increase would not only fund health care for more,than ... and,tobacco-related health care costs and save thousands of lives., ...
Cached Medicine News:Health News:D.I.S.C. Scores First Sponsorship Deal as Official Medical Center of the Los Angeles Kings 2Health News:STAAR Surgical Announces Third Quarter 2007 Earnings Release Date and Conference Call 2Health News:Cancer Prevention Coalition: The Breast Cancer Awareness Month Misleads Women 2Health News:Cancer Prevention Coalition: The Breast Cancer Awareness Month Misleads Women 3Health News:'Corrective' sex education may make sexual offenders more dangerous 2Health News:March of Dimes Selects Pennsylvania Girl as 2008 National Ambassador 2Health News:New Report: Increasing Oregon's Cigarette Tax Will Reduce Smoking, Save Lives and Save Money 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
For the quantitative determination of aspartate aminotransferase (AST) in human serum. The reagents are used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: